Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1395 participants.

Also called NCT07931807

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,395 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07931807
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07931807. Randomized; single masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours
Acronym
ORIENTAL-MeVO2
Condition
Medium Vessel Occlusion Stroke (MeVO)
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tenecteplase
Intervention (Procedure)
Endovascular Treatment
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China (class: other)

Record details

Record id
cardio:ct-nct07931807
Content hash
ec1507e68ae401ccfcb7d14367760de94bc2606fe2ca5d826347674c25813492